PMID- 28745207
OWN - NLM
STAT- MEDLINE
DCOM- 20180515
LR  - 20180515
IS  - 1873-4251 (Electronic)
IS  - 1570-162X (Linking)
VI  - 15
IP  - 4
DP  - 2017
TI  - HIV Drug Resistance Testing in a Resource Limited Setting with High Viral 
      Diversity: The First Twenty Eight Months Experience.
PG  - 297-305
LID - 10.2174/1570162X15666170725143835 [doi]
AB  - BACKGROUND: First line antiretroviral therapy in a resource-limited setting 
      consists of nucleotide and non-nucleotide reverse transcriptase inhibitors. 
      Protease inhibitors are the hub of second line therapy. The decision to change 
      antiretroviral therapy for a patient is frequently presumptive because of the 
      lack of genotypic resistance tests in routine follow-up. We describe here the 
      resistance profiles observed in patients with varying terms of antiretroviral 
      therapy in Cameroon after implementation of HIV genotypic resistance testing in 
      routine practice. METHODS: HIV genotypic resistance testing was carried out on 
      consecutive samples received between August 2013 and November 2015. Protease 
      (Prot) and reverse transcriptase (Rt) genes of the HIV genome were amplified, 
      sequenced and analyzed for drug resistance mutations following the algorithm set 
      up by the French National Agency for research on HIV/AIDS and viral hepatitis. 
      RESULTS: Specimens from a total of 167 patients infected with non-B HIV subtypes 
      were received during the study period. Overall 61.7% patients had viral loads of 
      more than 3log copies/ml, suggesting treatment failure. Among the 72 patients on 
      first line, 56 (77.8%) were resistant to Lamivudine, 57 (79.1%) to Efavirenz and 
      58 (80.6%) to Nevirapine. Overall, more patients (75.0%) on first line 
      antiretroviral therapy harbored multi-drug resistance compared to their 
      counterparts on second line (25.8%). CONCLUSION: This study revealed that a group 
      of patients with antiretroviral therapy failure harbored multi-drug resistance 
      mutations related to the majority of drugs in the first line regimen. Therefore, 
      HIV resistance testing could be a useful tool to improve HIV care in resource 
      limited settings like Cameroon where treatment options are limited.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - Ngo-Malabo, Elodie Teclaire
AU  - Ngo-Malabo ET
AD  - Virology department, Centre Pasteur of Cameroon, Yaounde. Cameroon.
FAU - Ngoupo, Paul Alain
AU  - Ngoupo PA
AD  - Virology department, Centre Pasteur of Cameroon, Yaounde. Cameroon.
FAU - Sadeuh-Mba, Serge Alain
AU  - Sadeuh-Mba SA
AD  - Virology department, Centre Pasteur of Cameroon, Yaounde. Cameroon.
FAU - Akongnwi, Emmanuel
AU  - Akongnwi E
AD  - Virology department, Centre Pasteur of Cameroon, Yaounde. Cameroon.
FAU - Banai, Robert
AU  - Banai R
AD  - Virology department, Centre Pasteur of Cameroon, Yaounde. Cameroon.
FAU - Ngono, Laure
AU  - Ngono L
AD  - Virology department, Centre Pasteur of Cameroon, Yaounde. Cameroon.
FAU - Bilong-Bilong, Charles Felix
AU  - Bilong-Bilong CF
AD  - Laboratory of Parasitology and Ecology, University of Yaounde I Faculty of 
      Science, Yaounde. Cameroon.
FAU - Kfutwah, Anfumbom
AU  - Kfutwah A
AD  - Virology department, Centre Pasteur of Cameroon, Yaounde. Cameroon.
FAU - Njouom, Richard
AU  - Njouom R
AD  - Virology department, Centre Pasteur of Cameroon, Yaounde. Cameroon.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Curr HIV Res
JT  - Current HIV research
JID - 101156990
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Human Immunodeficiency Virus Proteins)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-HIV Agents/*therapeutic use
MH  - Cameroon
MH  - *Drug Resistance, Viral
MH  - Female
MH  - Genotyping Techniques/*methods
MH  - HIV/*drug effects
MH  - HIV Infections/*drug therapy
MH  - Human Immunodeficiency Virus Proteins/genetics
MH  - Humans
MH  - Male
MH  - Microbial Sensitivity Tests/*methods
MH  - Middle Aged
MH  - Mutation, Missense
MH  - Sequence Analysis, DNA
MH  - Treatment Failure
MH  - Young Adult
OTO - NOTNLM
OT  - Cameroon
OT  - HIV
OT  - Treatment failure
OT  - Viral Diversity
OT  - drug resistance
OT  - genotyping resistance test
OT  - mutation
OT  - resource limited setting
EDAT- 2017/07/27 06:00
MHDA- 2018/05/16 06:00
CRDT- 2017/07/27 06:00
PHST- 2017/04/05 00:00 [received]
PHST- 2017/06/07 00:00 [revised]
PHST- 2017/07/21 00:00 [accepted]
PHST- 2017/07/27 06:00 [pubmed]
PHST- 2018/05/16 06:00 [medline]
PHST- 2017/07/27 06:00 [entrez]
AID - CHR-EPUB-84985 [pii]
AID - 10.2174/1570162X15666170725143835 [doi]
PST - ppublish
SO  - Curr HIV Res. 2017;15(4):297-305. doi: 10.2174/1570162X15666170725143835.